Vilazodone Hydrochloride Tablet
Product Images NDC 60505-4372

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 60505-4372). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label Principal Display Panel 10 mg Tablets 30 Bottle Label (10mg 30label)

Label for Vilazodone Hydrochloride Tablets, 10 mg strength, in a package of 30 tablets. The label indicates oral dosage form and includes storage instructions. Manufactured by MSN Laboratories Private Limited, India, and labeled for Apotex Corp. The label also features an NDC number 60505-4372-3 and a barcode.*

FDA Label Image

Package Label Principal Display Panel 20 mg Tablets 30 Bottle Label (20mg 30label)

Label for Vilazodone Hydrochloride Tablets 20 mg in a 30-tablet package from Apotex Corp. The label includes storage instructions, manufacturer MSN Laboratories Private Limited, and mentions it is for oral use. The NDC code 60505-4373-3 and barcode are also visible.*

FDA Label Image

Package Label Principal Display Panel 40 mg Tablets 30 Bottle Label (40mg 30label)

Label for Vilazodone Hydrochloride Tablets 40 mg, a prescription oral tablet. The label indicates a package size of 30 tablets and notes manufacturer Apotex Corp, with manufacturing by MSN Laboratories Private Limited in India. It includes storage instructions and a pharmacist dispensing note.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure of vilazodone hydrochloride, showing its molecular framework including indole, piperazine, and benzofuran moieties with a hydrochloride group.*

FDA Label Image

Figure 1 (Vii00 0013 02)

A scatter plot graph showing fold changes and 90% confidence intervals in pharmacokinetics parameters Cmax and AUC for vilazodone hydrochloride when co-administered with ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). The x-axis represents change relative to reference from 0.5 to 2.0.*

FDA Label Image

Figure 2 (Vii00 0013 03)

A chart depicting the fold change and 90% confidence interval in the pharmacokinetic parameters of various CYP and P-glycoprotein substrates relative to a reference. The graph shows changes for substrates including nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin, indicating their AUC, Cmax, Clrm, and Um values.*

FDA Label Image

Figure 3 (Vii00 0013 04)

A forest plot chart showing pharmacokinetic fold changes (Cmax and AUC) with 90% confidence intervals for various population subgroups, including age (>65 years), gender (females), and levels of renal and hepatic impairment (mild, moderate, severe). The chart compares these values relative to reference groups, illustrating variability in drug exposure parameters.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.